Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Two-Part, Accelerated Dose Titration Trial of CT-179 as Monotherapy in the Treatment of Recurrent Glioblastoma and in Combination With Radiation Therapy in the Treatment of Newly Diagnosed MGMT-Unmethylated Glioblastoma

NCT07739017 is registered in ClinicalTrials.gov with Olivia Newton-John Cancer Research Institute as lead sponsor.

NCT NCT07739017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07739017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Two-Part, Accelerated Dose Titration Trial of CT-179 as Monotherapy in the Treatment of Recurrent Glioblastoma and in Combination With Radiation Therapy in the Treatment of Newly Diagnosed MGMT-Unmethylated Glioblastoma
Lead sponsor
Olivia Newton-John Cancer Research Institute
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
September 30, 2028
Enrollment
54 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed mgmt unmethylated glioblastoma, recurrent glioblastoma